According to a 2016 consensus document for breast cancer management by Indian Council of Medical Research, more than 50% breast cancer patients are diagnosed at later stage. Breast cancer is the most invasive and common disease amongst Indian females with age adjusted rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000 women. Breast cancer projection states that the number of cases will go as high as 17,97,900 by 2020.
Commenting on the occasion Haruto Iwata, Managing Director Fujifilm India said, “Our association with Vijaya Medical Centre is a significant step in our collective attempt to fight against cancer. About 155,000 new cases of breast cancer are detected annually in India out of which 76,000 women die of breast cancer. With the increasing incidence of breast cancer diseases in female population, it is imperative for healthcare providers to step up and provide women the best and precise early detection screening facilities that can help save lives. Our state of the art AMULET INNOVALITY is one such product that has made early detection of breast cancer a reality for women all over the world. We are happy to bring this to our valued partner in Vishakhapatnam.”
Dr. Suman Kalagara, Managing Director, Vijaya Medical Centre said, “Our vision at Vijaya Medical Centre is to provide all the medical diagnostic services under one roof. Our partnership with Fujifilm is to strengthen the imaging facility for women in order to provide the finest treatment for breast cancer.
“The installation of the AMULET INNOVALITY at Vijaya Medical Centre is a milestone achieved in line with our pledge to raise awareness and promote early detection and treatment of breast cancer in India. We are grateful to Vijaya Medical Centre, for supporting us in this endeavor. The most common cause of death from breast cancer is delayed diagnosis therefore we would like to invite more such health care institutes to support our vision,” said Chander Shekhar Sibal, Executive Vice President & Head of Medical Division at Fujifilm India.
The installation of the Amulet Innovality at Vijaya Medical Centre has given the women of Vishakhapatnam access to early detection of Breast Cancer. The Amulet Innovality uses advanced tomosynthesis technology to enable the conversion of digital breast images into a 3-D reconstruction of the breast, in contrast to the flat images produced by traditional 2-D digital mammography. Reconstructed tomographic images reveal the internal structure of the breast, simplifying the detection of lesions that may be overlooked in a routine mammography. Amulet Innovality enables diagnosticians to obtain a clearer view of the breast tissue, facilitating identification of early stage breast cancer and reducing the need for additional tests and biopsies.
Several features of Amulet Innovality offer women a safe and personalised screening experience, making it easier for them to come for breast examinations. This unique system caters to the unique biological makeup of every woman: The Intelligent Automatic Exposure Control (i-AEC) defines the optimum X ray dosage for each breast type, compared to conventional AEC where the sensor position is fixed. A Direct Conversion flat panel detector with a 50 micron pixel resolution, and other advanced technological features also give this system a distinct edge over others. 50 micron resolution is best resolution and it helps detects cancer at a very early stage.
Mammography is the most powerful breast cancer detection tool. Mammograms don’t prevent breast cancer but they can save lives by finding breast cancers as early as possible. According to a report by WHO, Mammograms have been shown to reduce breast cancer mortality by around 20% in women by early detection.
Modern day digital mammography machine and tomosynthesis pick cancers early and involve only tiny radiation even less than a standard chest X ray. In future, digital mammography will become more and more common. Most oncologists agree that breast screening mammography should start at the age of 40 and earlier in patients with high risks like genetic predisposition (BRCA 1 & BRCA 2 antigen positive) and those with strong family history.